Reduced Relapse Rates in Multiple Sclerosis
What is an MS relapse?
Addressing the high rate of disease relapse following alloSCT in patients with AML
Multiple Sclerosis Research Outcomes
Ozanimod: long-term safety and efficacy in relapsing MS
Four-year efficacy and safety of evobrutinib for relapsing MS
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS
Multiple Sclerosis (MS)
Dr Jennifer Graves - The effect of biological age on disease progression
Is HSCT for MS overrated? [Neurologist reviews data VS. Tysabri, Ocrevus, and Gilenya]
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis
Switching from S1Ps or HETs to DRF: results from the EVOLVE-MS-1 study
AAN 2020 Data Release: Ofatumumab for Relapsing MS
Multiple Sclerosis: Important Metrics in Clinical Trials
Ozanimod's Consistent Efficacy in Long-Term Treatment for Multiple Sclerosis
Ublituximab: pending approval for relapsing MS
Toward a New Drug for Multiple Sclerosis
UNDERSTANDING MS RELAPSE
